Last edition
News about "Sanofi"
Sanofi and Partners Report Positive Phase 2 Results for AlphaMedix in Advanced GEP-NETs
AlphaMedix, which is developed by Orano Med and RadioMedix and now licensed to Sanofi, achieved all primary efficacy endpoints in the phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumours.
Sanofi | 08/10/2025 | By Dineshwori
Novavax, Sanofi Deepen Partnership to Include Matrix-M in Pandemic Influenza Vaccine Programme
The expanded partnership allows Sanofi to use Novavax’s Matrix-M adjuvant in its pandemic influenza vaccine candidate programme.
Sanofi | 01/10/2025 | By Dineshwori
US FDA Grants Fast Track Designation to AAV Gene Therapy by Sanofi
The US FDA has granted fast track designation to Sanofi’s SAR446268, an AAV gene therapy for juvenile and adult-onset myotonic dystrophy type 1 (DM1).
Sanofi | 23/09/2025 | By Dineshwori
Sanofi Drug Earns Fast Track Status for Wet AMD in US
Sanofi is evaluating SAR402663 in a Phase 1/2 trial (NCT06660667) for neovascular AMD. The gene therapy targets abnormal blood vessel growth, reduces retinal damage, and aims to eliminate the need for frequent intravitreal injections.
Sanofi | 11/09/2025 | By Dineshwori
Sanofi's Amlitelimab Achieves Key Milestone in Phase-III Trial for Atopic Dermatitis
Sanofi’s amlitelimab demonstrates sustained efficacy and improved disease outcomes, highlighting the potential to reshape the treatment for atopic dermatitis.
Sanofi | 04/09/2025 | By Dineshwori
US FDA Clears Sanofi's Wayrilz, First BTK Inhibitor for ITP
The US FDA approval was based on the pivotal LUNA 3 phase-III study, in which Sanofi’s Wayrilz met the primary and secondary endpoints, showing a positive impact on sustained platelet counts and other ITP symptoms.
Sanofi | 30/08/2025 | By Dineshwori | 105
UK Approves Sanofi's Teplizumab to Delay Onset of Stage 3 Type 1 Diabetes
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D.
Sanofi | 18/08/2025 | By Dineshwori | 102
Emcure Pharma Delivers Robust Performance Across All Businesses in Q1FY26: Satish Mehta
Emcure Pharmaceuticals reported strong financial results for the first quarter of FY26, demonstrating impressive growth in both domestic and international businesses.
Sanofi | 07/08/2025 | By Dineshwori | 162
Sanofi Acquires Vigil Neuroscience, Strengthens Neurodegenerative Disease Pipeline
Sanofi has completed its acquisition of Vigil Neuroscience, thereby strengthening its early-stage pipeline in neurology with the addition of VG-3927, an experimental drug candidate for Alzheimer's disease.
Sanofi | 07/08/2025 | By Dineshwori | 102
Sanofi to Acquire Vicebio for USD 1.6 Billion
Sanofi has entered into a definitive agreement to acquire Vicebio Ltd., a biopharma company developing next-generation respiratory vaccines, in a deal worth up to USD 1.6 billion, including an upfront payment of USD 1.15 billion.
Sanofi | 22/07/2025 | By Mrinmoy Dey | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy